N/A
N=24
Omega-3 Supplementation and Resistance Training
Sarcopenia · Dynapenia · Inflammation
Bottom Line
View on ClinicalTrials.gov: NCT02617511 ↗Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Sep 2023
Primary outcome: Primary: Tumor Necrosis Factor-alpha — 1.05; 0.93; 1.04; 1.18 pg/mL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Omega-3 Supplementation (Dietary_supplement); Placebo (Dietary_supplement)
- Age
- Older Adult · 65+ yrs
- Sex
- Male
- Sponsor
- University of Manitoba
- Primary completion
- Sep 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Tumor Necrosis Factor-alpha |
1.05; 0.93; 1.04; 1.18 | — |
| SECONDARY Interleukin-6 |
2.01; 1.84; 2.1; 2.19 | — |
| SECONDARY Lean Tissue Mass |
55.2; 55.8; 55.7; 56.5 | — |
| SECONDARY Leg Press Strength |
114.5; 105.7; 158.7; 142.0 | — |
| SECONDARY Timed up and go Test |
6.35; 5.91; 5.83; 5.62 | — |
| SECONDARY Bone Mineral Content |
3.18; 3.26; 3.19; 3.26 | — |
| SECONDARY Chest Press Strength |
51.4; 49.6; 67.2; 65.0 | — |
| SECONDARY 6 Minute Walk Test |
604.8; 622.5; 636.7; 646.4 | — |
Summary
The purpose of this project is to evaluate whether omega-3 fatty acid supplementation (combined eicosapentaenoic acid and docosahexaenoic acid [EPA/DHA] supplement) augments the effects of a 12-week resistance training program in older men. Outcome variables include inflammatory biomarkers in the systemic circulation, body composition and performance measures. The specific inflammatory markers in the blood include: C-reactive protein, tumor necrosis factor-α, interleukin-1β, and interleukin-6. Remaining parameters include: body composition (as assessed by dual energy x-ray absorptiometry), muscle strength (as assessed by chest press and leg press one-repetition maximum strength tests), and functional ability (as assessed by timed up and go test as well as the 6-minute walking test).
Eligibility Criteria
Inclusion Criteria
- equal to or greater than 65 years of age,
- male,
- they will not participate in a structured exercise program any more than 2-times per week.
Exclusion Criteria
- consumption of anti-inflammatory medication (which would confound the results in terms of the effects that the exercise and nutritional intervention is accomplishing),
- diagnosis with an inflammatory disease (such as inflammatory bowel disease or rheumatoid arthritis) as this is not the participant population we want to evaluate,
- consumption of any natural health products that have anti-inflammatory components to them (such as omega-3 fatty acids or omega-3 fortified eggs or more than 2 servings per week of fatty fish),
- current participation in an exercise program ≥ 2 times per week or current participation in a structured resistance training program > 1 time per week as we want to evaluate an untrained, sedentary population,
- has a mental or cognitive disability (such as dementia), and
- has a physical disability that would limit them from participating in a structured resistance training program.
Data sourced from ClinicalTrials.gov (NCT02617511). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.